Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Complicated Urinary Tract Infection Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Pyelonephritis
Interventions
CXA-201, Levofloxacin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
San Diego, California • Wheat Ridge, Colorado • Hialeah, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infections or Pyelonephritis
Interventions
Doripenem, Doripenem placebo, Cefepime, Cefepime placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Oakland, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sylmar, California • Royal Oak, Michigan • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced May 22, 2026, 3:47 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia
Interventions
Not listed
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced May 22, 2026, 3:47 AM EDT
Not listed Phase 3 Interventional
View directory record Official record
Conditions
Complicated Urinary Tract Infection Including Acute Pyelonephritis
Interventions
Combination of Imipenem/Cilastatin and XNW4107, Meropenem
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Abdominal Infection
Interventions
Vabomere, Best Available Therapy
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infection
Interventions
NXL104/ceftazidime, Imipenem/Cilastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infections
Interventions
Sulopenem, Sulopenem-Etzadroxil/Probenecid, Ertapenem, Ciprofloxacin, Amoxicillin-clavulanate
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
18 Years and older
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
15
States / cities
Bellflower, California • Chula Vista, California • La Mesa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced May 22, 2026, 3:47 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI), Urinary Tract Infection (Diagnosis)
Interventions
Treatment guided by the PCR results, Treatment guided by the C&S results
Diagnostic Test
Lead sponsor
Doc Lab Inc
Industry
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Jose, California • Albany, Georgia • Evans, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Pyelonephritis
Interventions
Ceftolozane/Tazobactam, Meropenem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Fosfomycin tromethamine, Levofloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Sylmar, California • Torrance, California • Decatur, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Urinary Tract Infections, Acute Pyelonephritis
Interventions
Cefepime/VNRX-5133 (taniborbactam), Meropenem
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Buena Park, California • Chula Vista, California • La Mesa, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
Interventions
ZTI-01, Piperacillin-tazobactam
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Pensacola, Florida • Augusta, Georgia • Columbus, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Acute Pyelonephritis
Interventions
Cefepime-zidebactam (FEP-ZID), Meropenem
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Fort Myers, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
cefepime/AAI101 combination, Piperacillin/tazobactam
Drug
Lead sponsor
Allecra
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Anaheim, California • Buena Park, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
Up to 3 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Little Rock, Arkansas • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 22, 2026, 3:47 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Not listed
Lead sponsor
Pathnostics
Industry
Eligibility
18 Years and older
Enrollment
3,308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infections
Interventions
Ceftazidime -avibactam, Cefepime
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 17 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
San Diego, California • Winston-Salem, North Carolina • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infections
Interventions
Eravacycline, Ertapenem, Placebo, Levofloxacin
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Fullerton, California • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis
Interventions
Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin, Saline
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Mobile, Alabama • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Complicated Urinary Tract Infection
Interventions
CXA-101, Ceftazidime
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 90 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Los Angeles, California • Orlando, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP), Complicated Urinary Tract Infection (cUTI), Ventilator Associated Bacterial Pneumonia (VABP)
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
3 Months to 17 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced May 22, 2026, 3:47 AM EDT